Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Annals of Oncology ◽

10.1093/annonc/mdz155.088 ◽

2019 ◽

Vol 30 ◽

pp. iv23-iv24 ◽

Cited By ~ 3

Author(s):

A. Fernández Montes ◽

N. Martinez Lago ◽

J. De la Cámara Gómez ◽

M. Covela Rúa ◽

A. Cousillas Castiñeiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

Faculty of 1000 evaluation for FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718009648.793485773 ◽

2013 ◽

Author(s):

Yiqian Nancy You ◽

Craig Messick

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Colorectal Cancer Patients ◽

First Line Treatment

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)

Annals of Oncology ◽

10.1093/annonc/mdt165 ◽

2013 ◽

Vol 24 (8) ◽

pp. 2062-2067 ◽

Cited By ~ 67

Author(s):

L. Fornaro ◽

S. Lonardi ◽

G. Masi ◽

F. Loupakis ◽

F. Bergamo ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Colorectal Cancer Patients ◽

First Line Treatment

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of Oncology ◽

10.1016/s0923-7534(21)00330-6 ◽

2016 ◽

Vol 27 ◽

pp. ix54

Author(s):

T. Ando ◽

S. Yuki ◽

H. Nakatsumi ◽

T. Muranaka ◽

A. Hosokawa ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Analysis Phase ◽

Administration Interval

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

British Journal of Cancer ◽

10.1038/s41416-018-0348-7 ◽

2018 ◽

Vol 120 (2) ◽

pp. 190-195 ◽

Cited By ~ 9

Author(s):

David Páez ◽

María Tobeña ◽

Julen Fernández-Plana ◽

Ana Sebio ◽

Anna C. Virgili ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

High Dose ◽

Efficacy And Safety ◽

A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients

Annals of Oncology ◽

10.1093/annonc/mdz154.024 ◽

2019 ◽

Vol 30 ◽

pp. iv135

Author(s):

F. Pietrantonio ◽

R. Lobefaro ◽

M. Antista ◽

R. Miceli ◽

A. Raimondi ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer

Cancer Science ◽

10.1111/cas.13943 ◽

2019 ◽

Vol 110 (3) ◽

pp. 1032-1043 ◽

Cited By ~ 10

Author(s):

Tadamichi Denda ◽

Daisuke Sakai ◽

Tetsuya Hamaguchi ◽

Naotoshi Sugimoto ◽

Takashi Ura ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

Second Line

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Cancer Communications ◽

10.1186/s40880-019-0374-8 ◽

2019 ◽

Vol 39 (1) ◽

pp. 28 ◽

Cited By ~ 1

Author(s):

Yuankai Shi ◽

Jin Li ◽

Jianming Xu ◽

Yan Sun ◽

Liwei Wang ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Open Label ◽

Phase Iii Trial ◽

HGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment

Annals of Oncology ◽

10.1093/annonc/mdy431.029 ◽

2018 ◽

Vol 29 ◽

pp. ix37

Author(s):

M. Dazai ◽

S. Yuki ◽

K. Sawada ◽

T. Muranaka ◽

Y. Kawamoto ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Double Blind ◽

Control Phase ◽

Randomized Control

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

British Journal of Cancer ◽

10.1038/sj.bjc.6603493 ◽

2007 ◽

Vol 96 (3) ◽

pp. 439-444 ◽

Cited By ~ 21

Author(s):

E Bajetta ◽

◽

M Di Bartolomeo ◽

R Buzzoni ◽

L Mariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Colorectal Cancer Patients ◽

First Line Treatment